Clearside Biomedical Suprachoroidal Delivery Technology to be Featured at Upcoming ASRS and OIS Medical Meetings – GlobeNewswire

- Multiple Podium and Poster Presentations on XIPERE and Gene Therapy Delivery Utilizing SCS Microinjector -

ALPHARETTA, Ga., July 07, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc.(Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS), announced today that several presentations will be delivered at the American Society of Retina Specialists (ASRS) Annual Meeting and the Ophthalmology Innovation Source (OIS) Retina Innovation Summit taking place July 13 16, 2022 in New York, NY.

Together with our partners, we will have a strong presence at the prominent OIS and ASRS meetings next week as we showcase the versatility of our proprietary suprachoroidal delivery platform, said Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer at Clearside Biomedical. Numerous podium and poster presentations will be given on U.S. FDA approved XIPERE, suprachoroidal delivery of gene therapy via our SCS Microinjector, as well as an overview of suprachoroidal delivery across preclinical and clinical studies.

OIS Retina Innovation Summit

ASRS Presentation

Dr. Glenn Yiu, et al. will deliver a podium presentation entitled, Biodistribution of suprachoroidal drug and viral vector delivery across animal models and human trials.

XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use: ASRS Partner Presentations

Clearsides SCS Microinjector: ASRS Partner Presentation

About Clearsides Suprachoroidal Space (SCS) Injection Platform and SCS Microinjector

Clearsides patented, proprietary suprachoroidal space (SCS) injection platform offers unprecedented access to the back of the eye where sight-threatening disease often occurs. Clearsides patented technology is designed to deliver drug to the suprachoroidal space located between the choroid and the outer protective layer of the eye, known as the sclera. The companys unique platform is inherently flexible and intended to work with established and new formulations of medications. Clearsides proprietary SCS Microinjector can be used to inject a wide variety of drug candidates into the SCS. The SCS Microinjector provides targeted delivery to potentially improve efficacy and compartmentalization of medication to reduce or eliminate toxic effects on non-diseased cells. The SCS Microinjector is composed of a syringe and two 30-gauge hollow microneedles of varying lengths, each less than 1.2 millimeters, with a custom-designed hub that optimizes insertion and suprachoroidal administration of drugs.

About XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use

XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, formerly known as CLS-TA, is a proprietary suspension of the corticosteroid triamcinolone acetonide for administration to the suprachoroidal space for the treatment of macular edema associated with uveitis. Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., has the exclusive license for the commercialization and development of XIPERE in the United States and Canada. Arctic Vision, a specialty ophthalmology company based in China, has the exclusive license for the commercialization and development of XIPERE, which they refer to as Arcatus, in Greater China, South Korea, Australia, New Zealand, India and the ASEAN Countries. XIPERE was approved by the U.S. Food and Drug Administration in October 2021 and is commercially available in the U.S.

Important Safety Information about XIPERE

Indication XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use is a corticosteroid indicated for the treatment of macular edema associated with uveitis.

IMPORTANT SAFETY INFORMATIONPatients should be monitored following injection for elevated intraocular pressure. See Dosage and Administration instructions in full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch + Lomb at 1-800-321-4576or FDA at 1-800-FDA-1088 or visit http://www.fda.gov/medwatch.

Please click here for full Prescribing Information.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). Clearsides SCS injection platform, utilizing the Companys proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearsides first product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially available in the U.S. For more information, please visit http://www.clearsidebio.com.

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as believe, expect, may, plan, potential, will, and similar expressions, and are based on Clearsides current beliefs and expectations. These forward-looking statements include statements regarding the potential benefits of therapies using Clearsides SCS Microinjector. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearsides reliance on third parties over which it may not always have full control, uncertainties regarding the COVID-19 pandemic and other risks and uncertainties that are described in Clearsides Annual Report on Form 10-K for the year ended December 31, 2021, filed with the U.S. Securities and Exchange Commission (SEC) on March 11, 2022, and Clearsides other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Clearside as of the date of this release, and Clearside assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

ALTITUDE is a trademark of REGENXBIO, Inc.

Investor and Media Contacts:

Jenny Kobin Remy Bernarda ir@clearsidebio.com(678) 430-8206

Source: Clearside Biomedical, Inc.

Read the original post:

Clearside Biomedical Suprachoroidal Delivery Technology to be Featured at Upcoming ASRS and OIS Medical Meetings - GlobeNewswire